ライフサイエンスコーパス: polymyalgia

1 GCA relapse heralded by symptoms of isolated polymyalgia rheumatica (1 case versus 5 in the placebo g

2 94 patients with giant cell arteritis and/or polymyalgia rheumatica (n = 25,581), inflammatory bowel

3 Polymyalgia rheumatica (PMR) and giant cell arteritis (G

4 Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely related conditi

5 Polymyalgia rheumatica (PMR) has an abrupt onset of infl

6 omic basis for joint disease localization in polymyalgia rheumatica (PMR) is poorly understood.

7 Polymyalgia rheumatica (PMR) is the second most common i

8 To evaluate the impact of polymyalgia rheumatica (PMR) on clinical outcomes and qu

9 Imaging studies in GCA and polymyalgia rheumatica (PMR) suggest that vasculitis can

10 GCA frequently overlaps with polymyalgia rheumatica (PMR), a rheumatic inflammatory c

11 In patients with polymyalgia rheumatica (PMR), a subclinical variant of G

12 /or visual abnormalities, fever, concomitant polymyalgia rheumatica (PMR), and histologic evidence of

13 nifestations are headache, jaw claudication, polymyalgia rheumatica (PMR), and visual symptoms, but 4

14 ic lupus erythematosus, psoriatic arthritis, polymyalgia rheumatica (PMR), giant cell arteritis, anky

15 of Rheumatology classification criteria for polymyalgia rheumatica (PMR).

16 ous cardiovascular diseases in patients with polymyalgia rheumatica (PMR).

17 n criteria were persistent disease activity (polymyalgia rheumatica activity score computed using the

18 ed to identify the pathological substrate of polymyalgia rheumatica and it is increasingly used to su

19 6 other AIDs; both shared associations with polymyalgia rheumatica and rheumatoid arthritis.

20 toms and clinical features characteristic of polymyalgia rheumatica and/or giant cell arteritis (GCA)

21 ence interval [CI] 1.64-1.84; range 1.52 for polymyalgia rheumatica and/or giant cell arteritis to 2.

22 Participants were patients with polymyalgia rheumatica and/or giant cell arteritis who w

23 ed clinical trial enrolled 101 patients with polymyalgia rheumatica at 17 hospitals in France from Fe

24 d as the resolution of signs and symptoms of polymyalgia rheumatica by week 12 and sustained normaliz

25 Among patients with active polymyalgia rheumatica despite prednisone therapy, tocil

26 Although polymyalgia rheumatica does not clearly impair survival

27 corticoid dose in patients with a relapse of polymyalgia rheumatica during glucocorticoid tapering.

28 More than half of patients with polymyalgia rheumatica have a relapse during tapering of

29 Polymyalgia rheumatica is a chronic, inflammatory disord

30 Polymyalgia rheumatica is an inflammatory disease produc

31 Polymyalgia rheumatica is an inflammatory disease that a

32 val (CI): 1.1-1.2), P=9.8 x 10(-11)) and for polymyalgia rheumatica near C6orf10 at rs6910071 (OR=1.5

33 Polymyalgia rheumatica occurred with similar frequency i

34 s cross-sectional study of 267 patients with polymyalgia rheumatica or giant cell arteritis found a G

35 such as anti-interleukin 6, in patients with polymyalgia rheumatica that is refractory to glucocortic

36 One patient with polymyalgia rheumatica who developed the inhibitor while

37 with nonstenosing vasculitis; and "isolated" polymyalgia rheumatica with myalgias, systemic inflammat

38 timate of 21 million for 1995), 711,000 have polymyalgia rheumatica, 228,000 have giant cell arteriti

39 nifestations are headache, jaw claudication, polymyalgia rheumatica, and visual symptoms.

40 medical record review: rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, psor

41 This issue provides a clinical overview of polymyalgia rheumatica, focusing on risk factors, diagno

42 Individuals with prior diagnoses of GCA, polymyalgia rheumatica, HIV, or transplant status were e

43 Several other disorders can mimic polymyalgia rheumatica.

44 h as muscle pains and stiffness diagnosed as polymyalgia rheumatica.

45 e for patients with glucocorticoid-dependent polymyalgia rheumatica.

46 lying therapeutic innovations to people with polymyalgia rheumatica.

47 atients with active glucocorticoid-dependent polymyalgia rheumatica.

48 ases, infections, and malignancies can mimic polymyalgia rheumatica.

49 may be clinically useful in the treatment of polymyalgia rheumatica.

50 ases in acute phase reactants are typical of polymyalgia rheumatica.